John G. Curd
9Patents
5h-index
13Co-inventors
56Inventor score
Filing activity: Nov 9, 1999 → Jul 16, 2015
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7820161B1 | Treatment of autoimmune diseases | Emerging Cross-Sectional Technologies | 121 | Expired |
| US7682612B1 | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody | Human Necessities | 78 | Expired |
| US8545843B2 | Treatment of vasculitis | Emerging Cross-Sectional Technologies | 49 | Active |
| US8206711B2 | Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies | Human Necessities | 19 | Active |
| US8946275B2 | Treatment of cancer using hypoxia activated prodrugs | Human Necessities | 5 | Active |
| US8410075B2 | Mannich base N-oxide drugs | Chemistry; Metallurgy | 1 | Active |
| US8048872B2 | Treatment of hyperproliferative diseases with vinca alkaloid N-oxide and analogs | Human Necessities | 1 | Active |
| US9993550B2 | Treatment of pemphigus | Emerging Cross-Sectional Technologies | 0 | Active |
| US8883775B2 | Treatment of hyperproliferative diseases with vinca alkaloid N-oxide analogs | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.